Surgical excision after neoadjuvant therapy with vismodegib for a locally advanced basal cell carcinoma and resistant basal carcinomas in Gorlin syndrome.
作者信息
Chang Anne Lynn S, Atwood Scott X, Tartar Danielle M, Oro Anthony E
出版信息
JAMA Dermatol. 2013 May;149(5):639-41. doi: 10.1001/jamadermatol.2013.30.
Abstract
摘要
相似文献
1
Surgical excision after neoadjuvant therapy with vismodegib for a locally advanced basal cell carcinoma and resistant basal carcinomas in Gorlin syndrome.
JAMA Dermatol. 2013 May;149(5):639-41. doi: 10.1001/jamadermatol.2013.30.
2
Basal cell carcinoma rebound after cessation of vismodegib in a nevoid basal cell carcinoma syndrome patient.
Dermatol Surg. 2012 Nov;38(11):1863-6. doi: 10.1111/j.1524-4725.2012.02513.x. Epub 2012 Jul 17.
3
Inhibiting the hedgehog pathway in patients with the basal-cell nevus syndrome.
N Engl J Med. 2012 Jun 7;366(23):2180-8. doi: 10.1056/NEJMoa1113538.
4
9q22.3 Microdeletion Syndrome with Multiple Basal Cell Carcinomas Treated with Vismodegib: Three Key Messages in One Patient.
Acta Derm Venereol. 2018 Feb 7;98(2):287-288. doi: 10.2340/00015555-2822.
5
Comment on basal cell carcinoma rebound after cessation of vismodegib in an individual with basal cell nevus syndrome.
Dermatol Surg. 2013 Sep;39(9):1413-4. doi: 10.1111/dsu.12250. Epub 2013 May 17.
6
Histologic changes in basal cell carcinoma after treatment with vismodegib.
Dermatol Surg. 2013 Nov;39(11):1703-5. doi: 10.1111/dsu.12281. Epub 2013 Jul 23.
7
Vismodegib in advanced basal-cell carcinoma.
N Engl J Med. 2012 Sep 6;367(10):970; author reply 970-1. doi: 10.1056/NEJMc1208003.
8
Inhibition of the hedgehog pathway in patients with basal-cell nevus syndrome: final results from the multicentre, randomised, double-blind, placebo-controlled, phase 2 trial.
Lancet Oncol. 2016 Dec;17(12):1720-1731. doi: 10.1016/S1470-2045(16)30566-6. Epub 2016 Nov 10.
9
Patient with Gorlin syndrome and metastatic basal cell carcinoma refractory to smoothened inhibitors.
JAMA Dermatol. 2014 Aug;150(8):877-9. doi: 10.1001/jamadermatol.2013.8744.
10
Vismodegib for radiation-induced multiple basal cell carcinomas (BCCs) of the scalp.
J Am Acad Dermatol. 2015 Nov;73(5):799-801. doi: 10.1016/j.jaad.2015.07.016. Epub 2015 Aug 25.
引用本文的文献
1
Assessment of Mammalian Target of Rapamycin Pathway Activation in Basal Cell Carcinoma as a New Therapeutic Approach.
Am J Dermatopathol. 2024 Sep 1;46(9):588-592. doi: 10.1097/DAD.0000000000002718. Epub 2024 Apr 23.
2
Real-world assessment and treatment of locally advanced basal cell carcinoma: Findings from the RegiSONIC disease registry.
PLoS One. 2022 Jan 14;17(1):e0262151. doi: 10.1371/journal.pone.0262151. eCollection 2022.
3
Basal cell carcinoma: multimodal treatment and the role of neoadjuvant vismodegib.
Autops Case Rep. 2019 Sep 27;9(4):e2019116. doi: 10.4322/acr.2019.116. eCollection 2019 Oct-Dec.
4
Long-term Response to Vismodegib in a Patient with Gorlin-Goltz Syndrome: A Case Report and Review of Pathological Mechanisms Involved.
Cureus. 2019 Aug 13;11(8):e5383. doi: 10.7759/cureus.5383.
5
New developments in the treatment of basal cell carcinoma: update on current and emerging treatment options with a focus on vismodegib.
Onco Targets Ther. 2018 Nov 23;11:8327-8340. doi: 10.2147/OTT.S135650. eCollection 2018.
6
Gorlin-Goltz syndrome.
Turk Pediatri Ars. 2017 Sep 1;52(3):173-177. doi: 10.5152/TurkPediatriArs.2017.2992. eCollection 2017 Sep.
7
Vismodegib for Locally Advanced Periocular and Orbital Basal Cell Carcinoma: A Review of 15 Consecutive Cases.
Plast Reconstr Surg Glob Open. 2017 Jul 21;5(7):e1424. doi: 10.1097/GOX.0000000000001424. eCollection 2017 Jul.
8
A Prognostic Dilemma of Basal Cell Carcinoma with Intravascular Invasion.
Plast Reconstr Surg Glob Open. 2016 Sep 27;4(9):e1046. doi: 10.1097/GOX.0000000000001046. eCollection 2016 Sep.
9
Combination Trimodality Therapy Using Vismodegib for Basal Cell Carcinoma of the Face.
Case Rep Oncol Med. 2015;2015:827608. doi: 10.1155/2015/827608. Epub 2015 Oct 4.
10
Regulation of the oncoprotein Smoothened by small molecules.
Nat Chem Biol. 2015 Apr;11(4):246-55. doi: 10.1038/nchembio.1776.
本文引用的文献
1
Initial assessment of tumor regrowth after vismodegib in advanced Basal cell carcinoma.
Arch Dermatol. 2012 Nov;148(11):1324-5. doi: 10.1001/archdermatol.2012.2354.
2
Efficacy and safety of vismodegib in advanced basal-cell carcinoma.
N Engl J Med. 2012 Jun 7;366(23):2171-9. doi: 10.1056/NEJMoa1113713.
3
Phosphoinositide 3-kinase signaling pathway mediated by p110α regulates invadopodia formation.
J Cell Biol. 2011 Jun 27;193(7):1275-88. doi: 10.1083/jcb.201009126.
4
Interfering with resistance to smoothened antagonists by inhibition of the PI3K pathway in medulloblastoma.
Sci Transl Med. 2010 Sep 29;2(51):51ra70. doi: 10.1126/scitranslmed.3001599.
5
Human GLI2 and GLI1 are part of a positive feedback mechanism in Basal Cell Carcinoma.
Oncogene. 2002 Aug 15;21(36):5529-39. doi: 10.1038/sj.onc.1205748.
Zotero 插件